Tag - BGBIO

Feature

BerGenBio pioneering cutting-edge AXL therapies to fight aggressive diseases

BerGenBio (OSE:BGBIO) is developing a pipeline of transformative drugs targeting AXL as a cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections.

July 16, 2024

Developments

BerGenBio announces NCI clinical collaboration with UT Health San Antonio and Swedish Orphan Biovitrum AV

BerGenBio ASA (OSE: BGBIO) has announced that it has entered into a clinical trial agreement with the Mays Cancer Center at UT Health San Antonio and Swedish Orphan Biovitrum AV to study BerGenBio’s selective AXL...

May 29, 2024

Markets

HCW ups BerGenBio to buy on positive outlook for bemcentinib

H.C. Wainwright upgraded BerGenBio (OSLO:BGBIO) to “buy” from “neutral” with a price target of NOK30. The stock closed at NOK6.70 on Nov. 25. “As 2022 is coming to a close, we believe now is an opportune time to step...

November 28, 2022

Developments

BerGenBio presents bemcentinib data in NSCLC; receives FDA fast track

BerGenBio ASA (OSE:BGBIO) will deliver an e-poster presentation at the online Society for Immunotherapy of Cancer meeting with preclinical and clinical data suggesting that bemcentinib restored response to anti-PD-1...

November 9, 2021

Tag - BGBIO

BerGenBio pioneering cutting-edge AXL therapies to fight aggressive diseases

BerGenBio announces NCI clinical collaboration with UT Health San Antonio and Swedish Orphan Biovitrum AV

HCW ups BerGenBio to buy on positive outlook for bemcentinib

BerGenBio presents bemcentinib data in NSCLC; receives FDA fast track

General

More